Prostate cancer screening with Prostate-Specific Antigen (PSA) testing: A retrospective study

Olgun Goktas

doi:10.12669/pjms.40.10.8558

Author(s)

Olgun Goktas Uludag University Family Health Center, 16059, Gorukle Campus-Nilufer, Bursa, Turkey.

Abstract

Objective: To evaluate the results of the prostate-specific antigen (PSA) test used in prostate cancer screening. Methods: This retrospective study was conducted on a total of 1106 male individuals, including 615 people (55.6%) aged 40-54, 379 people (34.3%) aged 55-69, and 112 individuals (10.1%) aged 70 and over. In the study, prostate-specific antigen (PSA) blood test results were performed on a total of 1106 male individuals aged 40 and over registered in the Uludag University Family Health Center, Bursa, Turkey during the 5-years between June 1, 2018, and May 31, 2023, were taken from the database and analyzed. Relationships with sociodemographic characteristics, comorbidities, and risk factors were examined. Data was analyzed using SPSS 25. Results: About 15.5% of the participants were married, 78.4% were single, and 6% were separated from their spouses or widows. The PSA values of the patients referred to the urologist were found to be significantly diferent between the ages of 55 and 69. It was determined that the PSA levels of the patients with benign prostatic hypertrophy and prostate cancer were higher than the patients without any finding, and the mean was 6.81±4.39 (p=0.01). Conclusion: In our study, it is important to diagnose benign prostatic hypertrophy or prostate cancer in patients aged 55-69 years, whose mean PSA levels were 6.81±4.39, and referred to a urologist. As a contribution to the discussions in the literature, we recommend that the patient with symptoms be referred to the urologist after the test request and the joint decision with the family physician.

Publication Details

Page(s) 2324-2330

DOI 10.12669/pjms.40.10.8558

Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 10, Year: 2024

Request the full text from PASTIC

Keywords

Screening, Screening, Prostate cancer, Detection, Prostate-specific antigen, Olgun Goktas, PSA testing

References

Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Cancer J Clin A .2021 .GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Global Cancer Statistics, 10(3) : 209-249.

Sagan A,McDaid D,Rajan S,Farrington J,McKee M. Screening J .2020 .(Policy Brief. , 35 : .

Aydin S. .2007 .Türkiye'de üriner sistem kanserlerin görülme sıklığı. Türk Üroloji Dergisi, 33(4) : 392-397.

Fenton JJ,Weyrich MS,Durbin S,Liu Y,Bang H,Melnikow J .2018 .Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 10(18) : 1914-1931.

Van Poppel H,Roobol MJ,Chapple CR,Catto JWF,N'Dov J,Sønksen J .2021 .Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol, 07(6) : 703-711.

Poppel VH,Albreht T,Basu P,Hogenhout R,Collen S,Roobol M .2022 .Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol, 10(9) : 562-572.

Magnani CJ,Li K,Seto T,McDonald KM,Blayney DW,Brooks JD,U.S. Preventive Services Task Force Guideline Changes. J Natl Compr Canc Netw JD .2018 .PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012. , 10(7) : 795-803.

Bergengren O,Pekala KR,Matsoukas K,Fainberg J,Mungovan SF,Bratt O .2023 .Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol, 04(2) : 191-206.

Preventive Services Task For US,Grossman DC,Curry SJ,Owens DK,Domingo KB,Caughey AB,Davidson KW .2018 .Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 10(18) : 1901-1913.

Ilic D,Djulbegovic M,Jung JH,Hwang EC,Zhou Q,Cleves A .2018 .Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ, 10 : 3519.

Jackson SD,Rue MRDL,Greenslade TP,John AM,Wahid S,Martin RM .2022 .Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostatespecific antigen testing. J Med Screen, 10(4) : 268-271.

Martin RM,Donovan JL,Turner EL,Metcalfe C,Young GJ,Walsh EI .2018 .Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA, 10(9) : 883-895.

Vickers A,O'Brien F,Montorsi F,Galvin D,Bratt O,Carlsson S .2023 .Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. -071082, 10 : .

Gandaglia G,Leni R,Bray F,Fleshner N,Freedland SJ,Kibel A .2021 .Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol, 09(6) : 877-892.

Zhu H,Jiu T,Wang D .2015 .Impact of polymorphisms of the DNA repair gene XRCC1 and their role in the risk of prostate cancer. Pak J Med Sci, 10(2) : 290-294.

Zhang S,Zhao S,Fu X .2019 .Intensity modulated radiotherapy in combination with endocrinotherapy in the treatment of middle and advanced Prostatic Cancer. Pak J Med Sci, 10(5) : 591-1269.

Höti N,Lih TS,Dong M,Mangold Z,Partin L,AW L .2023 .Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection. Cancers (Basel), 10(3) : 960.

Chang Y,Chang J,Wang H .2018 .Transurethral balloon dilatation of the Prostate and Transurethral Plasmakinetic resection of the Prostate in the treatment of Prostatic Hyperplasia. Pak J Med Sci, 10(3) : 736-739.

Lakes J,Arsov C .2019 .PSA-Screening und molekulare Marker (PSA screening and molecular markers). Urologe A, 10(5) : 486-493.

Feng J,Sun Q,Li J,Li TT .2021 .Reliability and validity test of VES-13 and analysis of influencing factors for the vulnerable condition of patients with advanced castration-resistant prostate cancer. Pak J Med Sci, 10(1) : 3095-141.

Clift AK,Coupland CA,Cox HJ,Pract J Gen .2021 .Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England,. , 10(703) : e157-e165.

Albertsen PC .2021 .PSA testing, cancer treatment, and prostate cancer mortality reduction: What is the mechanism? Urol Oncol. , 08(2) : 78-81.